|
Introduction
- Generic saturation coupled with a poor R&D pipeline is forcing
pharmaceutical companies to seek alternative ways of maintaining revenue
growth in the ever-competitive psychiatry sector. Surprisingly, despite
being long recognized as a costly problem, interest in patient compliance is
only just gaining momentum and effective patient compliance programs have
yet to become standard practice.
Scope of this report
- Analysis of the prevalence of noncompliance in schizophrenia, bipolar
disorder and depression with an overview of compliance improving strategies
- For these three disorders: discussion of general and side-effect specific
reasons for noncompliance
- Insight into the actions taken by care managers of noncompliant patients
- In-depth analysis of the perceived usefulness of approaches to tackle
noncompliance and the influence of education sources
Research and analysis highlights
- Players in the schizophrenia, bipolar disorder, and depression markets
lose millions of dollars in drug sales annually due to noncompliance.
Capturing this lost revenue is becoming ever important as the return on
investment of traditional lifecycle management strategies is dwindling.
- Pfizer and Eli Lilly have both implemented large compliance programs in
psychiatry, which have been well received by the medical community. The
popularity of these programs can be attributed to a patient-focused design,
which, among other benefits, has served the companies profile among
end-users.
- Ultimately, education to patients is a free service provided by companies.
If shown to improve treatment outcomes in controlled studies, companies
would be in a stronger position to convince payers and regulatory bodies to
advocate their brands over generics.
Key reasons to read this report
- Understand the key reasons causing noncompliance in schizophrenia, bipolar
disorder, and depression and the actions taken by therapists
- Benchmark your own patient compliance programs to those that have already
been conducted by other companies
- Optimize the communication of your compliance messages by recognizing the
most influential sources of information for these patient groups
| 
View Cart
